

Rafael E Jimenez

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8305167/publications.pdf>

Version: 2024-02-01

51
papers

1,266
citations

471371

17
h-index

377752

34
g-index

51
all docs

51
docs citations

51
times ranked

2153
citing authors

#	ARTICLE	IF	CITATIONS
1	A contemporary guide to chromosomal copy number profiling in the diagnosis of renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 512-524.	0.8	6
2	Morphologic overlap between low-grade oncocytic tumor and eosinophilic variant of chromophobe renal cell carcinoma. <i>Human Pathology</i> , 2022, 119, 114-116.	1.1	9
3	Renal Neoplasia in Polycystic Kidney Disease: An Assessment of Tuberous Sclerosis Complex-associated Renal Neoplasia and PKD1/TSC2 Contiguous Gene Deletion Syndrome. <i>European Urology</i> , 2022, 81, 229-233.	0.9	12
4	Cytogenetics of spermatocytic tumors with a discussion of gain of chromosome 12p in anaplastic variants. <i>Human Pathology</i> , 2022, 124, 85-95.	1.1	2
5	<i>A monument to suffering and to patience</i>: The harrowing journey of Nabby Adams through breast cancer. <i>Journal of Medical Biography</i> , 2022, , 096777202210977.	0.1	0
6	Renin Production by Juxtaglomerular Cell Tumors and Clear Cell Renal Cell Carcinoma and the Role of Angiotensin Signaling Inhibitors. <i>Mayo Clinic Proceedings</i> , 2022, 97, 2050-2064.	1.4	2
7	The 2019 Genitourinary Pathology Society (GUPS) White Paper on Contemporary Grading of Prostate Cancer. <i>Archives of Pathology and Laboratory Medicine</i> , 2021, 145, 461-493.	1.2	143
8	Renal neoplasia with papillary architecture involving the pelvicalyceal system. <i>Human Pathology</i> , 2021, 107, 46-57.	1.1	7
9	Practice patterns related to prostate cancer grading: results of a 2019 Genitourinary Pathology Society clinician survey. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 295.e1-295.e8.	0.8	6
10	Upgrade at excisional biopsy after a core needle biopsy diagnosis of classic lobular carcinoma in situ. <i>Surgery</i> , 2021, 169, 644-648.	1.0	9
11	Prostate MRI characteristics in patients with inflammatory bowel disease. <i>European Journal of Radiology</i> , 2021, 135, 109503.	1.2	1
12	A noncanonical AR addiction drives enzalutamide resistance in prostate cancer. <i>Nature Communications</i> , 2021, 12, 1521.	5.8	43
13	Tumor- and osteoclast-derived NRP2 in prostate cancer bone metastases. <i>Bone Research</i> , 2021, 9, 24.	5.4	17
14	Renal Neoplasia in Tuberous Sclerosis: A Study of 41 Patients. <i>Mayo Clinic Proceedings</i> , 2021, 96, 1470-1489.	1.4	31
15	MAP3K7-IKK Inflammatory Signaling Modulates AR Protein Degradation and Prostate Cancer Progression. <i>Cancer Research</i> , 2021, 81, 4471-4484.	0.4	5
16	Assessment of isochromosome 12p and 12p abnormalities in germ cell tumors using fluorescence in situ hybridization, single-nucleotide polymorphism arrays, and next-generation sequencing/mate-pair sequencing. <i>Human Pathology</i> , 2021, 112, 20-34.	1.1	19
17	MR characteristics of mucinous tubular and spindle cell carcinoma (MTSCC) of the kidney: comparison with clear cell and papillary subtypes of renal cell carcinoma. <i>Abdominal Radiology</i> , 2021, 46, 5250-5259.	1.0	6
18	Re: Stanley Weng, Renzo G. DiNatale, Andrew Silagy, et al. The Clinicopathologic and Molecular Landscape of Clear Cell Papillary Renal Cell Carcinoma: Implications in Diagnosis and Management. <i>Eur Urol</i> 2021;79:468-77. <i>European Urology</i> , 2021, 80, e62-e63.	0.9	2

#	ARTICLE	IF	CITATIONS
19	Fumarate Hydratase (FH) c.1431_1433dupAAA (p.Lys477dup) variant is not associated with FH protein deficiency and increased 2SC in two separate patients with renal neoplasia. <i>Human Mutation</i> , 2021, 42, 1362-1364.	1.1	1
20	Low-Grade Oncocytic Tumor of Kidney (CK7-Positive, CD117-Negative): Incidence in a single institutional experience with clinicopathological and molecular characteristics. <i>Human Pathology</i> , 2021, 114, 9-18.	1.1	37
21	Assessment of Risk of Hereditary Predisposition in Patients With Melanoma and/or Mesothelioma and Renal Neoplasia. <i>JAMA Network Open</i> , 2021, 4, e2132615.	2.8	4
22	Male breast cancer in the United States: Treatment patterns and prognostic factors in the 21st century. <i>Cancer</i> , 2020, 126, 26-36.	2.0	82
23	Secondary renal neoplasia following chemotherapy or radiation in pediatric patients. <i>Human Pathology</i> , 2020, 103, 1-13.	1.1	10
24	The Tsar's doctor: The selfless and devoted life of Dr Eugene Botkin. <i>Journal of Medical Biography</i> , 2020, 29, 096777202093502.	0.1	1
25	Defining clear cell papillary renal cell carcinoma in routine clinical practice. <i>Histopathology</i> , 2020, 76, 1093-1095.	1.6	17
26	Reply to On the proportion of male breast cancer among all breast cancers. <i>Cancer</i> , 2020, 126, 2034-2035.	2.0	1
27	Surveillance after prostate focal therapy. <i>World Journal of Urology</i> , 2019, 37, 397-407.	1.2	63
28	Incidence of succinate dehydrogenase and fumarate hydratase-deficient renal cell carcinoma based on immunohistochemical screening with SDHA/SDHB and FH/2SC. <i>Human Pathology</i> , 2019, 91, 114-122.	1.1	57
29	RUNX2 overexpression and PTEN haploinsufficiency cooperate to promote CXCR7 expression and cellular trafficking, AKT hyperactivation and prostate tumorigenesis. <i>Theranostics</i> , 2019, 9, 3459-3475.	4.6	22
30	A Prospective Correlation of Tissue Histopathology With Nucleic Acid Yield in Metastatic Castration-Resistant Prostate Cancer Biopsy Specimens. <i>Mayo Clinic Proceedings Innovations, Quality & Outcomes</i> , 2019, 3, 14-22.	1.2	8
31	A comparison of adult rhabdomyosarcoma and high-grade neuroendocrine carcinoma of the urinary bladder reveals novel PPP1R12A fusions in rhabdomyosarcoma. <i>Human Pathology</i> , 2019, 88, 48-59.	1.1	2
32	Phosphorylated RB Promotes Cancer Immunity by Inhibiting NF- κ B Activation and PD-L1 Expression. <i>Molecular Cell</i> , 2019, 73, 22-35.e6.	4.5	174
33	Evolution of androgen receptor variant (ARV) profiles in serial metastatic solid and liquid biopsies in metastatic castrate resistant prostate cancer (mCRPC) treated with abiraterone acetate/ prednisone (AA/P).. <i>Journal of Clinical Oncology</i> , 2019, 37, e16559-e16559.	0.8	2
34	Cellular fibroepithelial lesions of the breast: A long term follow up study. <i>Annals of Diagnostic Pathology</i> , 2018, 35, 85-91.	0.6	11
35	A contemporary review of male breast cancer: current evidence and unanswered questions. <i>Cancer and Metastasis Reviews</i> , 2018, 37, 599-614.	2.7	63
36	<i>TMPRSS2-ERG</i> Controls Luminal Epithelial Lineage and Antiandrogen Sensitivity in <i>PTEN</i> and <i>TP53</i> -Mutated Prostate Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 4551-4565.	3.2	51

#	ARTICLE	IF	CITATIONS
37	Treatment Outcomes for Pleomorphic Lobular Carcinoma In Situ of the Breast. <i>Annals of Surgical Oncology</i> , 2018, 25, 3064-3068.	0.7	14
38	DUB3 Promotes BET Inhibitor Resistance and Cancer Progression by Deubiquitinating BRD4. <i>Molecular Cell</i> , 2018, 71, 592-605.e4.	4.5	114
39	A transcriptome analysis of castration resistant prostate cancer metastases in a prospective cohort study reveals high expression of AKT pathway genes predictive of long term response to abiraterone acetate/prednisone.. <i>Journal of Clinical Oncology</i> , 2018, 36, 5038-5038.	0.8	1
40	Androgen Receptor Variant AR-V9 Is Coexpressed with AR-V7 in Prostate Cancer Metastases and Predicts Abiraterone Resistance. <i>Clinical Cancer Research</i> , 2017, 23, 4704-4715.	3.2	117
41	Genome-wide analysis of metastases to reveal association of pathway activation with abiraterone acetate/prednisone (AA/P) primary resistance and cell cycle proliferation pathway activation with response duration in metastatic castrate resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 5053-5053.	0.8	1
42	Determining the frequency of pathogenic germline variants from exome sequencing in patients with castrate-resistant prostate cancer. <i>BMJ Open</i> , 2016, 6, e010332.	0.8	32
43	Malakoplakia associated with prostatic adenocarcinoma. <i>Annals of Diagnostic Pathology</i> , 2016, 22, 33-37.	0.6	22
44	Association of androgen receptor variant 9 (AR-V9) mRNA expression levels in metastatic tissue with resistance to abiraterone acetate/prednisone (AA/P).. <i>Journal of Clinical Oncology</i> , 2016, 34, 5036-5036.	0.8	0
45	Mutational Landscapes of Sequential Prostate Metastases and Matched Patient Derived Xenografts during Enzalutamide Therapy. <i>PLoS ONE</i> , 2015, 10, e0145176.	1.1	26
46	Abdominal Pain and Ileocolitis in a 51-Year-Old Woman. <i>Gastroenterology</i> , 2015, 148, e9-e10.	0.6	0
47	Frequency of diagnosis of cancer or high-risk lesion at operation for pathologic nipple discharge. <i>Surgery</i> , 2015, 158, 988-995.	1.0	13
48	Androgen receptor (AR) based biomarker association with response to abiraterone acetate/prednisone (AA/P) in metastatic castrate resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 174-174.	0.8	0
49	Feasibility analysis of pathology and genetic yield from a prospective trial of tissue biopsies in metastatic castrate-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 249-249.	0.8	0
50	A molecular and clinico-pathological model for predicting abiraterone acetate/prednisone (AA/P) efficacy in metastatic castrate resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 5056-5056.	0.8	0
51	Predicting the biologic classification of phyllodes tumors from preoperative core needle biopsy and imaging findings.. <i>Journal of Clinical Oncology</i> , 2014, 32, 86-86.	0.8	0